UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis

NCT ID: NCT06933563

Last Updated: 2025-04-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-30
• Study Completion Date: 2027-11-30

Brief Summary

This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Myasthenia gravis. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.

Detailed Description

This is an investigator-initiated trial to evaluate the safety and efficacy of universal CD19/BCMA CAR T-cells in Relapsed or Refractory Myasthenia gravis.

Study intervention consists of a single infusion of universal CAR T-cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Interim analysis will be performed when participants finish the visit 90 days after CAR T-cell infusion.

Conditions

Myasthenia Gravis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

anti-CD19/BCMA CAR T-cells

Universal allogeneic CD19/BCMA CAR T-cells

Group Type: EXPERIMENTAL

UCAR T-cell group

Intervention Type: BIOLOGICAL

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Interventions

UCAR T-cell group

A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years

2. Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.

3. Patients with relapsed refractory myasthenia gravis (MG) who have positive abnormal antibodies, the total score of MG-ADL ≥5, and the eye muscle score < 50% of the total score; It is classified as Grade II-IV according to the 2020 MGFA diagnostic criteria.

4. Specific requirements include: i. Receiving standardized treatment with at least one immunosuppressant for more than 1 year, and having any of the following malcontrolled conditions: 1) persistent inability to affect daily life; 2) Aggravation of MG symptoms and/or crisis episodes occur despite standard treatment; 3) Inability to tolerate immunosuppressive therapy. ii. plasma exchange or maintenance of intravenous immunoglobulin therapy is required.

5. Functional requirements for major organs are as follows:

1. The bone marrow function needs to meet: a Neutrophil count ≥ 1.5× 10 ^ 9/L; b. Hemoglobin ≥90g/L: c. Platelets ≥ 80 × 10 ^ 9/L.

2. Liver function: ALT ≤ 3 × UL; AST ≤ 3×ULN# Total bilirubin ≤ 2.0 ×ULN (excluding Gilbert syndrome, total bilirubin ≤ 3.0 × ULN).

3. Renal function: creatinine clearance rate (CrCl) ≥ 30 ml/min(Cockcroft/Gault formula, excluding acute CrCl decline caused by the disease itself).

6. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.

7. Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.

Exclusion Criteria

1. Subjects with a history of severe drug allergies or allergic tendencies.

2. Presence or suspicion of uncontrolled or treatment-required fungal,bacterial, viral, or other infections.

3. Subjects with central nervous system diseases caused by autoimmune diseases or non-autoimmune diseases (including epilepsy, psychosis, organic brain syndrome, cerebral vascular accidents, encephalitis, central nervous system vasculitis).

4. Subjects with insufficient cardiac function.

5. Subjects with congenital immunoglobulin deficiencies.

6. History of malignancy within five years.

7. Subjects with end-stage renal failure.

8. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA titer higher than the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.

9. Subjects with psychiatric disorders and severe cognitive impairments.

10. Subjects who had participated in other clinical trials within 3 months prior to enrollment.

11. Subjects who have used immunosuppressive agents or biologics with therapeutic effects on the disease within five half-life before enrollment

12. Pregnant women or women planning to conceive

13. Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

He Huang

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, China

Countries

China

Central Contacts

He Huang

Role: CONTACT

hehuangyu@126.com

86-13605714822

Yongxian Hu

Role: CONTACT

Huyongxian2000@aliyun.com

86-15957162012

Facility Contacts

He Huang

Role: primary

hehuangyu@126.com

86-13605714822

Other Identifiers

QH-ZY-03

Identifier Type: -

Identifier Source: org_study_id